NanoMedical Systems

NanoMedical Systems, founded in 2006, is pioneering the field of nanotechnology in drug delivery with its innovative nStrada™ nanofluidics platform. The company's slogan, "Nanotechnology Transforming Drug Delivery," succinctly reflects its core mission. Utilizing its proprietary technology, the company specializes in the development of advanced drug-delivery devices capable of sustained release of chronic therapies. These devices, suitable for subcutaneous implantation, can accommodate various drugs, including small molecules, peptides, and proteins. The nStrada™ devices set themselves apart from traditional polymer-based implants and depots, offering a superior performance characterized by steady-state drug concentrations within a few days and consistent release throughout the implant's duration. This stands in stark contrast to the initial burst release and prolonged timeframe for achieving steady-state concentrations associated with existing solutions. NanoMedical Systems operates within the biotechnology sector, with its headquarters located in the United States. The company secured a significant $3.00M grant investment on 14 August 2018, indicative of the industry and investor confidence in its pioneering technology. Notably, the specific investors involved in this round are not disclosed. In summary, NanoMedical Systems holds great promise in revolutionizing drug delivery through its nanofluidics platform, and its recent grant investment underscores the recognition and support the company has garnered within the industry.